ASLAN CEO Carl Firth On A New Paradigm for Drug Development In Asia: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Asia continues to increase in importance for global clinical trial programs. Big pharmas such as Novartis and AstraZeneca are building up their own R&D sites while Eli Lilly and Pfizer are creating virtual R&D networks, taking advantage of the large naïve patient population and other efficiencies in Asia to accelerate drug development.
You may also be interested in...
ASLAN Gets Global Rights To Almirall RA Candidate, Third Deal In Less Than A Year For Singapore Startup
ASLAN Pharmaceuticals branches out from oncology for its third compound, but the formula is the same: in-license for Asia and find a CRO.
Singapore's ASLAN Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds
Singapore's ASLAN Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds